Details of Disease

General Information of Disease (ID: DISDJJ5G)

• Disease Name: Coronary ischemia
• Disease Class: BA50-BA51: Coronary ischemia
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISDJJ5G: Coronary ischemia
• ICD Code:
  ICD-11: ICD-11: BA50-BA51
  Expand ICD-11: 'BA5Z
  Expand ICD-10: 'I25; 'I25.0; 'I25.8; 'I25.9
• Disease Identifiers:
  MONDO ID: MONDO_0006715
  MESH ID: D023921
  UMLS CUI: C0242231
  MedGen ID: 66859
  HPO ID: HP:0005145
  SNOMED CT ID: 233970002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACY-001	DM5DZM1	Phase 1	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 14 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
SLC25A1	TTTD730	Limited	Biomarker	[2]
ADCY2	TTBQ9IM	Strong	Genetic Variation	[3]
CETP	TTFQAYR	Strong	Genetic Variation	[4]
DFFA	TTYVQ9C	Strong	Genetic Variation	[5]
HRH2	TTQHJ1K	Strong	Biomarker	[6]
IGF1	TTT6LOU	Strong	Biomarker	[7]
IGF1R	TTQFBMY	Strong	Biomarker	[7]
ITGAV	TTT1R2L	Strong	Biomarker	[8]
KLK1	TT5T3P6	Strong	Genetic Variation	[9]
MDK	TTV8UE7	Strong	Biomarker	[10]
MYH7	TTNIMDP	Strong	Biomarker	[6]
OLR1	TTKSND3	Strong	Biomarker	[11]
PRKCE	TT57MT2	Strong	Biomarker	[12]
SRGN	TTCHB06	Strong	Altered Expression	[13]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
PCYT1A	DEQYXD4	Strong	Biomarker	[14]
SULT1E1	DESTKG6	Strong	Genetic Variation	[15]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LAD1	OT6YGTVX	Strong	Biomarker	[16]
MLXIPL	OTR9MLLW	Strong	Genetic Variation	[17]
NPPA	OTMQNTNX	Strong	Biomarker	[6]
PHACTR1	OTAMPX9V	Strong	Genetic Variation	[18]
TCP1	OT1MGUX9	Strong	Biomarker	[14]
TNNI1	OT4GG8ED	Strong	Altered Expression	[19]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024462)
• [2] Application of speCtraL computed tomogrAphy to impRove specIficity of cardiac compuTed tomographY (CLARITY study): rationale and design.BMJ Open. 2019 Mar 1;9(3):e025793. doi: 10.1136/bmjopen-2018-025793.
• [3] Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease.Cardiovasc Res. 1999 Mar;41(3):746-53. doi: 10.1016/s0008-6363(98)00246-6.
• [4] Four polymorphisms of cholesteryl ester transfer protein gene and coronary stenosis in a Tunisian population.J Cardiovasc Med (Hagerstown). 2012 Sep;13(9):546-53. doi: 10.2459/JCM.0b013e3283569b24.
• [5] Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis.Gene. 2019 May 25;698:170-178. doi: 10.1016/j.gene.2019.02.074. Epub 2019 Mar 6.
• [6] Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery.Br J Pharmacol. 2003 Apr;138(8):1505-16. doi: 10.1038/sj.bjp.0705205.
• [7] Impairment of myocyte contractility following coronary artery narrowing is associated with activation of the myocyte IGF1 autocrine system, enhanced expression of late growth related genes, DNA synthesis, and myocyte nuclear mitotic division in rats.Exp Cell Res. 1993 Aug;207(2):348-60. doi: 10.1006/excr.1993.1202.
• [8] Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation.Cardiovasc Res. 2002 Mar;53(4):952-62. doi: 10.1016/s0008-6363(01)00547-8.
• [9] Association of serum levels of AngII, KLK1, and ACE/KLK1 polymorphisms with acute myocardial infarction induced by coronary artery stenosis.J Renin Angiotensin Aldosterone Syst. 2016 Jun 21;17(2):1470320316655037. doi: 10.1177/1470320316655037. Print 2016 Apr-Jun.
• [10] Neointima formation in a restenosis model is suppressed in midkine-deficient mice.J Clin Invest. 2000 Feb;105(4):489-95. doi: 10.1172/JCI7208.
• [11] Association of LOXIN, a new functional splicing isoform of the OLR1 gene, with severity and prognostic localization of critical coronary artery stenoses.J Cardiovasc Med (Hagerstown). 2014 May;15(5):391-6. doi: 10.2459/JCM.0b013e3283624251.
• [12] Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol.Cardiovasc Res. 2006 Aug 1;71(3):537-47. doi: 10.1016/j.cardiores.2006.05.011. Epub 2006 May 10.
• [13] The association between serum serglycin level and coronary artery disease severity in patients with stable angina pectoris.Kardiol Pol. 2018;76(4):783-790. doi: 10.5603/KP.2018.0007. Epub 2018 Jan 9.
• [14] Computed tomography angiography-derived fractional flow reserve (CT-FFR) for the detection of myocardial ischemia with invasive fractional flow reserve as reference: systematic review and meta-analysis.Eur Radiol. 2020 Feb;30(2):712-725. doi: 10.1007/s00330-019-06470-8. Epub 2019 Nov 6.
• [15] Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate.Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6545-6550. doi: 10.26355/eurrev_201810_16070.
• [16] PET/CT evaluation of (18)F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions' formation?.J Nucl Cardiol. 2017 Jun;24(3):1075-1084. doi: 10.1007/s12350-015-0370-6. Epub 2016 Mar 7.
• [17] C771G (His241Gln) polymorphism of MLXIPL gene, TG levels and coronary artery disease: a case control study.Anatol J Cardiol. 2015 Jan;15(1):8-12. doi: 10.5152/akd.2014.5135. Epub 2014 Feb 10.
• [18] Genome-wide association study in a Lebanese cohort confirms PHACTR1 as a major determinant of coronary artery stenosis.PLoS One. 2012;7(6):e38663. doi: 10.1371/journal.pone.0038663. Epub 2012 Jun 20.
• [19] Increased serum levels of troponin I and lesions in coronary angiography in hemodialysed patients.Rocz Akad Med Bialymst. 2005;50:311-3.